FindTrial
Sign In

A comparative evaluation of unani formulation with rosuvastatin in the management of dyslipidaemia

A Randomized Clinical Study On Dyslipidaemia and Comparative Evaluation Of Unani Formulation With Rosuvastatin In Its Management - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/04/065396
Enrollment
60
Registered
2024-04-08
Start date
Unknown
Completion date
Unknown
Last updated
2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E669- Obesity, unspecified

Interventions

Intervention1: Sufoof of unani formulation: Unani formulation will be given 5 gm BD in powder form orally after meal for 3 months Control Intervention1: Tablet Rosuvastatin: Tablet Rosuvastatin 10mg

Sponsors

Department of Moalejat Faculty of unani medicine Ajmal khan tibbya college
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients in age group of 30-60 years Patients of either gender Patient willing to sign the written informed consent Clinically stable patients of dyslipidemia with following subjective and objective parameters Subjective parameters: Patient showing any one of the following symptoms will be asked to go for required investigations & will be included in the study accordingly. Increasing body weight Dyspnoea on exertion Fatigue Xanthelasma Corneal arcus Joint pain Patients having any two of the following will be included in the study: Total Serum cholesterol ( 200-300 mg/dl) Serum triglyceride (160-300 mg/dl) LDL (130-190 mg/dl) HDL (30-60 mg/dl) LDL (30-50 mg/dl)

Exclusion criteria

Exclusion criteria: Patient below 30 years and above 60 years Any uncontrolled systemic illness Any type of liver disease Patient of CAD Uncontrolled type 2 Diabetes Mellitus Hyperthyroidism and Hypothyroidism Pregnant and lactating women Alcoholic Patient who fails to give consent In case of worsening of symptoms patient may be withdrawn from trial and be shifted to standard treatment.

Design outcomes

Primary

MeasureTime frame
Improvement in objective parameters Objective assessment (Serum Total Cholesterol, LDL, HDL, VLDL, Serum Triglyceride)Timepoint: 90 days on monthly follow up—

Secondary

MeasureTime frame
Improvement in subjective parameters Subjective assessments Increasing body weight Dyspnoea on exertion Fatigue Xanthelasma Corneal arcus Joint painTimepoint: 90 days on fortnightly follow up—

Countries

India

Contacts

Public ContactMD HAMZA AHMAD

Ajmal khan tibbya college Aligarh Muslim University Aligarh

tanzeel1967@gmail.com948123337

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026